Skip to main
BSX

Boston Scientific (BSX) Stock Forecast & Price Target

Boston Scientific (BSX) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 45%
Buy 55%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Boston Scientific's positive outlook is supported by anticipated growth in critical medical procedure markets, with a projected 5-10% increase in combined atrial fibrillation (AF) ablation and left atrial appendage closure (LAAC) procedures stemming from recent trial results. The company's forecasts indicate that the global AFib market may expand from $9 billion to $15 billion by 2028, showcasing a compound annual growth rate (CAGR) that is expected to drive significant revenue increases, particularly as newer technologies and catheters are introduced. Additionally, positive survey results from healthcare professionals suggest an expectation of a substantial volume increase in procedures, averaging around 18%, following the outcomes of pivotal trials, highlighting strong market confidence and demand for Boston Scientific's innovative products.

Bears say

Boston Scientific is facing a negative outlook primarily due to a significant decline in the market shares of its radiofrequency (RF) and cryoablation products, with RF procedures projected to decrease from 34% to 23% and cryoablation from 25% to 20% by 2030. Additionally, the company is grappling with challenges such as slower-than-expected uptake of its product portfolio, limited operating leverage, and heightened debt levels, all of which could adversely impact financial performance and growth. Furthermore, ongoing pricing pressures in its core businesses, combined with risks from new competitors and potential delays in product approvals, pose further threats to Boston Scientific’s future profitability.

Boston Scientific (BSX) has been analyzed by 20 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 55% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Boston Scientific and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Boston Scientific (BSX) Forecast

Analysts have given Boston Scientific (BSX) a Buy based on their latest research and market trends.

According to 20 analysts, Boston Scientific (BSX) has a Buy consensus rating as of Apr 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $100.95, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $100.95, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Boston Scientific (BSX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.